The estimated Net Worth of Darren S Cline is at least $4.2 Million dollars as of 28 May 2020. Mr. Cline owns over 7,356 units of GW Pharmaceuticals stock worth over $515 and over the last 10 years he sold GWPH stock worth over $4,199,687. In addition, he makes $0 as Chief Commercial Officer - U.S. at GW Pharmaceuticals.
Sign up
Mr. Cline GWPH stock SEC Form 4 insiders trading
Darren has made over 25 trades of the GW Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 7,356 units of GWPH stock worth $515 on 28 May 2020.
The largest trade he's ever made was exercising 12,761 units of GW Pharmaceuticals stock on 13 December 2016 worth over $312,006. On average, Darren trades about 3,154 units every 44 days since 2015. As of 28 May 2020 he still owns at least 7,356 units of GW Pharmaceuticals stock.
You can see the complete history of Mr. Cline stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Darren Cline biography
Darren Cline serves as Chief Commercial Officer - U.S. of the Company. Darren Cline is an accomplished biopharmaceutical executive with over 25 years of commercial experience, including hematology and oncology, orphan and ultra- orphan arenas. Mr. Cline is Executive Vice President, Commercial at Seattle Genetics, Inc., where he oversees all marketing, sales, and managed markets. He was directly involved in the commercial build out for the launch of Adcetris, an antibody-based biologic the US Food and Drug Administration approved for treatment of certain hematologic cancers; he played an integral role driving Adcetris’ continued growth to over $300 million in revenue. Prior to Seattle Genetics, Mr. Cline was at Alexion Pharmaceuticals, where he was part of the initial commercial leadership team for the Soliris launch, helping to build out key sales functions that were instrumental in Soliris becoming a billion-dollar brand. Mr. Cline received his undergraduate degree from San Diego State University and his MBA from Pepperdine University. Mr. Cline is also currently a non-executive director of Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics.
How old is Darren Cline?
Darren Cline is 55, he's been the Chief Commercial Officer - U.S. of GW Pharmaceuticals since 2019. There are 7 older and 5 younger executives at GW Pharmaceuticals. The oldest executive at GW Pharmaceuticals is William Waldegrave, 73, who is the Non-Executive Independent Director.
What's Darren Cline's mailing address?
Darren's mailing address filed with the SEC is C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at GW Pharmaceuticals
Over the last 6 years, insiders at GW Pharmaceuticals have traded over $60,899,192 worth of GW Pharmaceuticals stock and bought 7,200 units worth $48,960 . The most active insiders traders include Geoffrey W Dr Guy, James Noble, and Justin D. Gover. On average, GW Pharmaceuticals executives and independent directors trade stock every 10 days with the average trade being worth of $8,011. The most recent stock trade was executed by Douglas B. Snyder on 6 April 2021, trading 8,400 units of GWPH stock currently worth $152,208.
What does GW Pharmaceuticals's logo look like?
Complete history of Mr. Cline stock trades at GW Pharmaceuticals, Seagen Inc, Stemline Therapeutics, and Pliant Therapeutics
GW Pharmaceuticals executives and stock owners
GW Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Justin Gover,
Chief Executive Officer, Executive Director -
Geoffrey Guy,
Executive Chairman of the Board -
Volker Knappertz,
Chief Medical Officer -
Douglas Snyder,
Chief Legal Officer -
Scott Giacobello,
Chief Financial Officer -
Christopher Tovey,
Chief Operating Officer -
Adam George,
Managing Director - U.K., Company Secretary -
Cabot Brown,
Non-Executive Independent Director -
James Noble,
Non-Executive Independent Director -
Catherine Mackey,
Non-Executive Independent Director -
Alicia Secor,
Non-Executive Independent Director -
William Waldegrave,
Non-Executive Independent Director -
David Gryska,
Independent Director -
Stephen Schultz,
Vice President, Investor Relations -
Darren Cline,
Chief Commercial Officer - U.S. -
Thomas G Lynch,
Director -
Julian S Gangolli,
President, North America